Chimeras - no longer a myth.
Since its first successful application less than 15 years ago, allogeneic marrow transplantation has been used with continuously improving results for the treatment of severe aplastic anemia, leukemia and congenital immunodeficiency syndromes. With this background, a recent meeting(∗) provided an excellent opportunity to critically review problems and achievements of marrow transplant and non-transplant approaches to the treatment of malignant and nonmalignant lymphohemopoietic disorders.